Description

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

 

Vaxneuvance (with Dr consultation)

Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for important disease-causing shared serotype 3 and unique serotypes 22F and 33F compared to PCV13.

With this expanded indication, VAXNEUVANCE is the first pneumococcal conjugate vaccine approved in almost a decade to help protect pediatric populations against invasive pneumococcal disease.

 

Who should get pneumococcal vaccines

• Children under 2 years old: The standard regimen includes a primary series of 3 doses at 2, 4 and 6 months and a booster dose at 12-15 months.
• Aged 2 or above : Single dose of pneumococcal conjugate vaccine is recommended.

 

 

Invasive pneumococcal disease (IPD) is an infection caused by the bacterium Streptococcus pneumoniae, or pneumococcus. While there are approximately 100 different types of S. pneumoniae, called serotypes, a smaller number of serotypes are responsible for IPD in children. Serotypes 3, 22F and 33F are three of the top five serotypes causing childhood cases of IPD. IPD can lead to hospitalization or death. Some examples of IPD are bacteremia (an infection in the blood) and meningitis (an infection of the coverings of the brain and spinal cord), which can also result in long-term neurological complications. Children under the age of 2 are particularly vulnerable to IPD.

 

VAXNEUVANCE, Merck’s 15-valent pneumococcal conjugate vaccine, consists of purified capsular polysaccharides from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to CRM₁₉₇ carrier protein. VAXNEUVANCE is indicated for active immunization of individuals 6 weeks of age and older for the prevention of invasive disease caused by the S. pneumoniae serotypes contained in the vaccine. The FDA initially approved VAXNEUVANCE in July 2021.

 

Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf

and Patient Information/Medication Guide for VAXNEUVANCE at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_ppi.pdf.

 

 

Instructions for use:
• The first dose must be given within 90 days after payment; All doses must be completed within 5-13 months after the first dose.
• Please show your confirmation information, order number, registered full name and phone number for verification.

 

Terms and Conditions:
• This voucher is only valid for Trinity Medical Centre.
• The first dose must be given within 90 days after purchase of this voucher. This voucher can be used at Central, Causeway Bay or Tsim Sha Tsui Trinity Medical Centre. The validity period will not be extended by this voucher.
• Please make an appointment for the service in advance. The appointment and all services must be completed within the validity period.
• This voucher is non-refundable and cannot be redeemed for full or partial cash.
• You must bring this ticket to the front desk when you register.
• This voucher cannot be used with any other special offers and promotions.
• This voucher is not valid after expiration (except for COVID-19 policy).
• If this voucher is lost or stolen, we will not accept any liability and will not provide any reissue in such case.
• If you have any questions, please call 2192 7022 or email tmc@trinitymedical.com.hk
• Trinity Medical Centre reserves the right to amend the above Terms and Conditions without prior notice. In case of any disputes, Trinity Medical Centre reserves all rights for final decision.